



## Acquisition of own shares and options

### BRUSSELS, Belgium, 23 August 2011 – 19:30 (CET) – regulated information

In application of art. 207 of the Royal Decree executing the Company Code and according to Article 6 of the law of May 2, 2007 on the disclosure of large shareholdings, UCB SA publishes having acquired 2,471,405 UCB shares on 17 August 2011 OTC at a price of € 30.3642. The highest Brussels stock exchange price on 17 August 2011 was € 30.665. UCB has also acquired (between 6 and 17 June 2011) 800,000 options on UCB shares as follows:

Purchase date	Expiry date	Exercise date	Number
Between 6 and 17 June 2011	17 May 2013	each day until the expiry date	200,000
	16 May 2014	each day until the expiry date	180,000
	15 May 2015	each day until the expiry date	160,000
	20 May 2016	each day until the expiry date	140,000
	19 May 2017	each day until the expiry date	120,000

As a consequence, the new weighted average number of ordinary shares<sup>[1]</sup> (used to calculate the earnings per share of the company) as of today is 178.6 million versus 179.5 million as reported on 30th June 2011.

**UCB S.A. - Allée de la Recherche, 60 - 1070 Bruxelles - RPM 0403.053.608**

[1] Weighted average number of ordinary shares: The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of shares bought back or issued during the period, multiplied by a time-weighting factor.

#### **For further information**

Antje Witte, Investor Relations, UCB  
T +32.2.559.9414, [antje.witte@ucb.com](mailto:antje.witte@ucb.com)

#### **About UCB**

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

#### **Forward-looking statements**

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins,



*capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.*

*There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.*

*Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.*